A Phase 3 interventional study of cytarabine and daunorubicin in Leukemia, sponsored by Alliance for Clinical Trials in Oncology. Completed at 176 sites in 2 countries. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Alliance for Clinical Trials in Oncology · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing midostaurin in Leukemia, Myeloid, Acute — 3 open to participants now, 5 under way, 1 of them phase 3. midostaurin · Leukemia, Myeloid, Acute.
Among the 28 studies testing midostaurin in Leukemia, Myeloid, Acute, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 4 in phase 3, and was the 3rd registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →3 of the 28 studies testing midostaurin in Leukemia, Myeloid, Acute are open now, in 3 countries. Recruiting first, the newest first:
Richard Stone, MD · Sites in United States
Ages 18–75
Technische Universität Dresden · Sites in Germany
Ages 18–75
University Hospital, Toulouse · Sites in France
Ages 18–60
By country, each count listing its studies:
midostaurin: first FDA approval 2017 (RYDAPT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 59 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 17 · Phase 3 5
First in 2002; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 717 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 34 across the 28 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 28 have an industry lead sponsor. The 10 most frequent:
Alliance for Clinical Trials in Oncology is the lead sponsor of 509 studies on the registry; 28 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
17 studies in Leukemia, Myeloid, Acute by Alliance for Clinical Trials in Oncology: 1 open now, 2 under way, none of them phase 3. Of 13 finished, 4 (31%) have results posted.
Among the 17 studies in Leukemia, Myeloid, Acute by Alliance for Clinical Trials in Oncology, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2008, is one of 3 in phase 3, and was the 10th registered.
Alliance for Clinical Trials in Oncology’s Leukemia, Myeloid, Acute studies by the year they started, since 1996.
3 of the studies testing midostaurin in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00819546Richard Stone, MDRAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | 2026-12 |
| NCT06313437Richard Stone, MDRevumenib in Combination With 7+3 + Midostaurin in AML | 2027-03-02 |
| NCT04385290Technische Universität DresdenCombination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing midostaurin in Leukemia, Myeloid, Acute, from their registry updates:
Among Alliance for Clinical Trials in Oncology’s 17 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to find out which is better. This research is being done because it is unknown whether the addition of midostaurin to chemotherapy treatment is better than chemotherapy treatment alone. Midostaurin has been tested in over 400 patients and is being studied in a number of illnesses, including AML, colon cancer, and lung cancer. Midostaurin blocks an enzyme, produced by a gene known as FLT3, that may have a role in the survival and growth of AML cells. Not all leukemia cells will have the abnormal FLT3 gene. This study will focus only on patients with leukemia cells with the abnormal FLT3 gene.
In this study, patients will receive either the experimental agent (midostaurin) or placebo combined with chemotherapy treatment. Patients are stratified according to FLT3 mutation status (internal tandem duplication [ITD] allelic ratio \< 0.7 vs ITD allelic ratio ≥ 0.7 vs tandem kinase domain [TKD]). There are three parts to the study treatment: remission induction therapy, remission consolidation therapy and continuation therapy.
Remission Induction Therapy:
Remission Consolidation (Four Remission Consolidation Cycles):
Midostaurin/Placebo Continuation Therapy:
The primary and secondary objectives of this study are:
Primary objective:
Secondary objectives:
There is a pharmacokinetic sub-study (CALGB 60706) within CALGB 10603. This embedded companion study must be offered to all patients enrolled on CALGB 10603, although patients may opt not to participate in CALGB 60706.
After study entry, patients are followed periodically for up to 10 years.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
This study's enrollment of 717 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →Alliance for Clinical Trials in Oncology is the lead sponsor of 509 studies on the registry; 28 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Documentation of Disease:
Age Requirement:
Prior Therapy:
No prior chemotherapy for leukemia or myelodysplasia with the following exceptions:
Pregnancy and Nursing Status:
Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or commit to TWO acceptable methods of :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
Drug: cytarabine · Drug: daunorubicin · Drug: midostaurin · Drug: dexamethasone acetate
Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with placebo. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with placebo for twelve (12) months.
Drug: cytarabine · Drug: daunorubicin · Other: placebo · Drug: dexamethasone acetate
Given IV
Given IV
Given orally
Given orally
ocular medication administration
Overall Survival (OS)
Overall survival (OS) was defined as the time interval from randomization to death from any cause. The median OS with 95% CI was estimated using the Kaplan-Meier method.
Time frame: Duration of study (Up to 10 years)
Event- Free Survival
Event free survival (EFS) was defined as the time from randomization until the earliest qualifying event, including: failure to obtain a CR on or before 60 days of initiation of protocol therapy; relapse; or death from any cause. Patients alive and event free at the time of analysis were censored on the date of last clinical assessment. The median EFS with 95% CI was estimated using the Kaplan-Meier method. Due to a higher than expected transplant rate, EFS was promoted to be a key secondary endpoint.
Time frame: Duration of study (Up to 10 years)
Overall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the Transplant
Overall survival (OS) was defined as the time interval from randomization to death from any cause. Any participants who received a stem cell transplant were censored at the time of transplant. The median OS with 95% CI was estimated using the Kaplan-Meier method.
Time frame: Duration of study (Up to 10 years)
Complete Response Rate
Percentage of participants who achieved a complete response (CR). A CR was defined as normalization of blood counts and a marrow showing less than 5% blasts occurring on or before day 60.
Time frame: Induction therapy (up to 60 days)
Disease-free Survival (DFS)
Disease free survival (DFS) is defined as the time from documentation of first CR at any time to the first of relapse or death from any cause in participants who achieved a CR.
Time frame: Duration of study (Up to 10 years)
DFS Rate One Year After Completing the Planned Continuation Phase
Time frame: 30 months
Between May 2008 and October 2001, 3,277 participants were pre-registered. Of those, 900 participants had a documented FLT3 mutation. 717 participants were enrolled onto this study.
| Milestone | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo |
|---|---|---|
| Started | 360 | 357 |
| Completed | 69 | 51 |
| Not completed | 291 | 306 |
| Withdrew: Adverse event | 32 | 22 |
| Withdrew: Death | 18 | 18 |
| Withdrew: Withdrawal by subject | 22 | 40 |
| Withdrew: Induction failure | 24 | 35 |
| Withdrew: Disease progression | 58 | 58 |
| Withdrew: Alternative therapy | 109 | 107 |
| Withdrew: Other disease or participant decisions | 23 | 23 |
| Withdrew: Never treated | 5 | 3 |
Overall survival (OS) was defined as the time interval from randomization to death from any cause. The median OS with 95% CI was estimated using the Kaplan-Meier method.
| months | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo |
|---|---|---|
| Overall Survival (OS) | 74.7 (31.5 to NA) | 25.6 (18.6 to 42.9) |
Event free survival (EFS) was defined as the time from randomization until the earliest qualifying event, including: failure to obtain a CR on or before 60 days of initiation of protocol therapy; relapse; or death from any cause. Patients alive and event free at the time of analysis were censored on the date of last clinical assessment. The median EFS with 95% CI was estimated using the Kaplan-Meier method. Due to a higher than expected transplant rate, EFS was promoted to be a key secondary endpoint.
| months | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo |
|---|---|---|
| Event- Free Survival | 8.2 (5.4 to 10.7) | 3.0 (1.9 to 5.9) |
Overall survival (OS) was defined as the time interval from randomization to death from any cause. Any participants who received a stem cell transplant were censored at the time of transplant. The median OS with 95% CI was estimated using the Kaplan-Meier method.
| months | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo |
|---|---|---|
| Overall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the Transplant | NA (NA to NA) | NA (27.4 to NA) |
Percentage of participants who achieved a complete response (CR). A CR was defined as normalization of blood counts and a marrow showing less than 5% blasts occurring on or before day 60.
| percentage of participants | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo |
|---|---|---|
| Complete Response Rate | 59 (54 to 64) | 54 (48 to 59) |
Disease free survival (DFS) is defined as the time from documentation of first CR at any time to the first of relapse or death from any cause in participants who achieved a CR.
| months | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo |
|---|---|---|
| Disease-free Survival (DFS) | 26.7 (19.4 to NA) | 15.5 (11.3 to 23.5) |
Results for this outcome have not been posted.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction and Consolidation Chemotherapy Plus Midostaurin | — | 157/355 (44.2%) | 321/355 (90.4%) |
| Induction and Consolidation Chemotherapy Plus Placebo | — | 154/354 (43.5%) | 324/354 (91.5%) |
| Event | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo |
|---|---|---|
| Platelet count decreasedInvestigations | 155/355 | 146/354 |
| Hemoglobin decreasedBlood and lymphatic system disorders | 154/355 | 148/354 |
| Neutrophil count decreasedInvestigations | 145/355 | 146/354 |
| Febrile neutropeniaBlood and lymphatic system disorders | 105/355 | 110/354 |
| FatigueGeneral disorders | 95/355 | 98/354 |
| NauseaGastrointestinal disorders | 98/355 | 91/354 |
| DiarrheaGastrointestinal disorders | 89/355 | 89/354 |
| VomitingGastrointestinal disorders | 70/355 | 65/354 |
| Rash desquamatingSkin and subcutaneous tissue disorders | 59/355 | 66/354 |
| Leukocyte count decreasedInvestigations | 41/355 | 47/354 |
| Event | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo |
|---|---|---|
| Platelet count decreasedInvestigations | 311/355 | 313/354 |
| Hemoglobin decreasedBlood and lymphatic system disorders | 312/355 | 311/354 |
| Neutrophil count decreasedInvestigations | 308/355 | 308/354 |
| NauseaGastrointestinal disorders | 258/355 | 226/354 |
| Febrile neutropeniaBlood and lymphatic system disorders | 246/355 | 238/354 |
| DiarrheaGastrointestinal disorders | 228/355 | 219/354 |
| FatigueGeneral disorders | 221/355 | 220/354 |
| Rash desquamatingSkin and subcutaneous tissue disorders | 201/355 | 200/354 |
| VomitingGastrointestinal disorders | 188/355 | 168/354 |
| Ear, nose and throat examination abnormalGastrointestinal disorders | 112/355 | 112/354 |
| Age, Continuous(years) | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo | Total |
|---|---|---|---|
| Median | 47.1 (19 to 59.8) | 48.6 (18 to 60.9) | 47.9 (18.0 to 60.9) |
| Sex: Female, Male(Participants) | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo | Total |
|---|---|---|---|
| Female | 186 | 212 | 398 |
| Male | 174 | 145 | 319 |
| Ethnicity (NIH/OMB)(Participants) | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 7 | 16 |
| Not Hispanic or Latino | 103 | 107 | 210 |
| Unknown or Not Reported | 248 | 243 | 491 |
| Race (NIH/OMB)(Participants) | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 8 | 5 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 9 | 17 |
| White | 147 | 128 | 275 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 195 | 213 | 408 |
| Region of Enrollment(participants) | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo | Total |
|---|---|---|---|
| Canada | 4 | 9 | 13 |
| United States | 117 | 106 | 223 |
| Germany | 148 | 157 | 305 |
| Belgium | 3 | 5 | 8 |
| France | 3 | 2 | 5 |
| Netherlands | 3 | 2 | 5 |
| Australia | 0 | 2 | 2 |
| Spain | 7 | 15 | 22 |
| Austria | 7 | 5 | 12 |
| Italy | 61 | 44 | 105 |
| Czech Republic | 5 | 6 | 11 |
| Slovakia | 2 | 2 | 4 |
| Hungary | 0 | 2 | 2 |
| FLT3 mutational subtype(participants) | Induction and Consolidation Chemotherapy Plus Midostaurin | Induction and Consolidation Chemotherapy Plus Placebo | Total |
|---|---|---|---|
| TKD (No ITD) | 81 | 81 | 162 |
| ITD Allelic ratio <0.7 | 171 | 170 | 341 |
| ITD Allelic ratio >=0.7 | 108 | 106 | 214 |
Showing the first 100 of 176 sites across 2 countries. Choose a country and city above to see the rest.
Ran from Apr 2008 to primary completion in Jul 2016, 99 months.
Results were first posted in Feb 2017, 7 months after primary completion.
Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's 99 months is above that.
Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Midostaurin
Alliance for Clinical Trials in Oncology →